A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, ...

Half of the participants received a weekly injection of two milligrams of the drug exenatide, which is a GLP-1 receptor agonist similar to medicines such as Ozempic or Wegovy. The other half of ...

Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the successful ...

While it is one of the GLP-1 receptor agonists, Exenatide is not as powerful weight loss drug as the newer drugs in the market. However, experts stated that there is no evidence suggesting newer ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

Lixisenatide is an older drug in the same class as Novo Nordisk ... earlier study in Parkinson’s of a similar GLP-1 agonist, exenatide, which was published in The Lancet in 2017.

While many drugs in this class are relatively new ... Some case reports noted concerns over exenatide and semaglutide worsening depressive symptoms, and a larger study suggested a slightly increased ...

Prior data suggest that the more even drug exposure with exenatide LAR may translate into an improved efficacy and side-effect profile. Liraglutide, an acylated GLP1 analogue that requires daily ...

While many drugs in this class are relatively new ... Some case reports noted concerns over exenatide and semaglutide worsening depressive symptoms, and a larger study suggested a slightly ...